YD Bio Limited Ordinary Shares
YDESHealthcare|Biotechnology|TW
$5.97
-1.21 (-16.85%)
DCF Value
$0.12
Cash / Share
$0.09
Financials
Financial Snapshot
Market Cap
$422.9M
Enterprise Value
$416.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$3.0M
Cash & Investments
$2.7M
Net Cash
$2.7M
Free Cash Flow (TTM)
-$1.2M
Operating CF (TTM)
-$1.2M
Debt/Equity
-0.00
Cash Runway & Burn Rate
Cash on Hand
$2.7M
Quarterly Burn
$294.0K
Monthly Burn
$98.0K
Est. Runway
~9.1 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $693.8K | $5.4K | $14.1K | $87.1K | $3.1M | $6.0M | $2.7M | |
| Operating Cash Flow | -$253.6K | -$688.4K | -$3.0M | -$55.7K | -$1.8M | -$6.6M | -$1.2M | |
| Free Cash Flow | -$253.6K | -$688.4K | -$3.0M | -$55.9K | -$4.7M | -$8.0M | -$1.2M | |
| Capital Expenditure | $5.00 | -$5.00 | $0.00 | -$290.00 | -$2.9M | -$1.4M | -$3.00 | |
| Financing Cash Flow | $117.7M | $1.1M | -$97.3M | $113.9K | $7.7M | $10.9M | -$6.8M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $350.1K | $510.4K | $596.8K | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $196.7K | $355.0K | $639.0K | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $153.4K | $155.4K | -$42.1K | $0.00 | |
| R&D | $0.00 | $0.00 | $0.00 | $0.00 | $491.4K | $1.6M | $0.00 | |
| SG&A | $344.2K | $1.7M | $2.3M | $160.6K | $1.1M | $3.6M | $1.4M | |
| Operating Income | -$344.2K | -$1.7M | -$2.3M | -$9.8K | -$1.5M | -$5.3M | -$1.4M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $2.1K | $772.00 | $0.00 | $0.00 | |
| Pretax Income | -$2.5M | $8.7M | $3.8M | $17.6K | -$1.4M | -$8.3M | -$3.0M | |
| Net Income | -$2.5M | $8.7M | $3.8M | $13.6K | -$1.4M | -$8.3M | -$3.0M | |
| EPS (Diluted) | -0.17 | 0.59 | 0.41 | 0.00 | -0.56 | -0.12 | -0.99 | |
| EBITDA | -$2.5M | $8.7M | $3.8M | $22.2K | -$1.3M | -$8.1M | -$3.0M | |
| Shares Out. (M) | 14.63 | 14.63 | 9.29 | 70.10 | 4.15 | 66.72 | 3.41 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $693.8K | $5.4K | $14.1K | $87.1K | $3.1M | $6.0M | $2.7M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $830.8K | $129.6K | $202.7K | $271.7K | $3.5M | $9.7M | $5.6M | |
| Total Assets | $117.6M | $118.1M | $17.9M | $321.2K | $6.9M | $13.8M | $10.1M | |
| Total Current Liabilities | $302.2K | $2.0M | $5.6M | $298.2K | $263.1K | $1.6M | $1.1M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $17.8M | $9.1M | $6.7M | $298.2K | $274.0K | $16.6M | $5.6M | |
| Stockholders' Equity | $99.8M | $109.0M | $11.2M | $23.0K | $6.6M | -$2.9M | $4.5M | |
| Retained Earnings | -$15.2M | -$6.5M | -$6.5M | -$515.5K | -$1.9M | -$10.2M | -$3.5M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$253.6K | -$688.4K | -$3.0M | -$55.7K | -$1.8M | -$6.6M | -$1.2M | |
| Capital Expenditure | $5.00 | -$5.00 | $0.00 | -$290.00 | -$2.9M | -$1.4M | -$3.00 | |
| Free Cash Flow | -$253.6K | -$688.4K | -$3.0M | -$55.9K | -$4.7M | -$8.0M | -$1.2M | |
| Investing Cash Flow | -$116.7M | -$1.1M | $100.4M | -$290.00 | -$2.9M | -$1.4M | $7.9M | |
| Financing Cash Flow | $117.7M | $1.1M | -$97.3M | $113.9K | $7.7M | $10.9M | -$6.8M | |
| Issuance of Stock | $117.7M | $0.00 | $0.00 | $53.0K | $7.9M | $10.7M | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | -$101.5M | $0.00 | $0.00 | $0.00 | -$7.9M | |
| Net Debt Issuance | $0.00 | $1.1M | $4.2M | -$32.6K | -$33.0K | $0.00 | $1.1M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | $693.8K | -$688.4K | $8.7K | $57.0K | $3.0M | $2.9M | -$33.7K |
Dilution Tracker
Shares outstanding grew 356.2% over 5 years — significant dilution
Shares Outstanding
71M
5-Year Share Growth
+356.2%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 14.63 | 14.63 | 9.29 | 70.10 | 4.15 | 66.72 | 3.41 | |
| Change vs Prior % | — | 0.0% | -36.5% | 654.2% | -94.1% | 1509.3% | -94.9% | |
| Stock Issuance | $117.7M | $0.00 | $0.00 | $53.0K | $7.9M | $10.7M | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | -$101.5M | $0.00 | $0.00 | $0.00 | -$7.9M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | 43.8% | 30.4% | -7.1% | — | |
| Operating Margin % | — | — | — | -2.8% | -286.5% | -883.3% | — | |
| Net Margin % | — | — | — | 3.9% | -276.6% | -1392.6% | — | |
| EBITDA Margin % | — | — | — | 6.4% | -251.0% | -1357.8% | — | |
| FCF Margin % | — | — | — | -16.0% | -930.3% | -1346.6% | — | |
| ROE % | -2.5% | 8.0% | 33.8% | 59.0% | -21.4% | 291.0% | -445.1% | |
| ROA % | -2.2% | 7.4% | 21.1% | 4.2% | -20.6% | -60.3% | -60.3% | |
| ROIC % | -0.3% | -1.5% | -18.8% | -10.7% | -22.1% | -43.4% | -43.4% | |
| R&D / Revenue % | — | — | — | 0.0% | 96.3% | 268.4% | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 45.8% | 16.9% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 1.2% | -127.1% | |
| Operating Income | 0.0% | -400.4% | -34.9% | 99.6% | -14746.5% | -260.6% | |
| Net Income | 0.0% | 443.0% | -56.5% | -99.6% | -10509.7% | -488.8% | |
| EPS (Diluted) | 0.0% | 447.1% | -30.5% | -100.0% | -280100.0% | 78.6% | |
| Operating Cash Flow | 0.0% | -171.4% | -339.1% | 98.2% | -3200.2% | -259.1% | |
| Free Cash Flow | 0.0% | -171.4% | -339.1% | 98.1% | -8386.3% | -69.3% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 226.1% | |
| SG&A Expense | 0.0% | 400.4% | 34.9% | -93.1% | 601.6% | 222.0% | |
| Total Assets | 0.0% | 0.4% | -84.8% | -98.2% | 2037.0% | 100.7% | |
| Book Value / Share | 0.0% | 9.2% | -83.8% | -100.0% | 484473.5% | -102.7% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | -52.6% | -70.0% | |
| Diluted Shares | 0.0% | 0.0% | -36.5% | 654.2% | -94.1% | 1509.3% |
Valuation
P/E (TTM)At Loss
10Y Low / Med / High20.41 / 29.37 / 60200.00
P/S708.53
10Y Low / Med / High97.81 / 1362.74 / 2410.38
P/B-139.48
10Y Low / Med / High1.62 / 7.57 / 36703.00
EV/EBITDAAt Loss
10Y Low / Med / High20.24 / 29.52 / 37935.32
EV/Revenue698.48
10Y Low / Med / High91.71 / 1352.69 / 2410.27
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.12
Cash / Share
$0.09
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -70.82 | 20.41 | 29.37 | 60200.00 | -21.50 | -101.58 | -49.75 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 2410.38 | 97.81 | 1362.74 | 708.53 | |
| P/B Ratio | 1.76 | 1.62 | 9.99 | 36703.00 | 7.57 | -284.80 | -139.48 | |
| EV/EBITDA | -69.11 | 20.24 | 29.52 | 37935.32 | -36.54 | -99.63 | -51.44 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 2410.27 | 91.71 | 1352.69 | 698.48 |
Analyst Estimates & Quality
Altman Z-Score
44.49
Safe
Piotroski F-Score
2
Weak